{
    "organizations": [],
    "uuid": "069d3df858a1572212d86adb6146f9bfddef57cc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cocrystal-pharma-posts-qtrly-net-l/brief-cocrystal-pharma-posts-qtrly-net-loss-of-about-1-6-mln-idUSASC0A1RY",
    "ord_in_thread": 0,
    "title": "BRIEF-Cocrystal Pharma Posts Qtrly Net Loss Of About $1.6 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 11 (Reuters) - Cocrystal Pharma Inc:\n* COCRYSTAL PHARMA REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* COCRYSTAL PHARMA INC - FOR CC-42344, SEES TO INITIATE PHASE 1 STUDY EVALUATING CC-42344 FOR TREATMENT OF INFLUENZA IN Q4 2018\n* COCRYSTAL PHARMA INC QTRLY NET LOSS OF ABOUT $1.6 MILLION VERSUS A NET LOSS OF ABOUT $2.5 MILLION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-11T20:15:00.000+03:00",
    "crawled": "2018-05-12T17:18:49.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "cocrystal",
        "pharma",
        "inc",
        "cocrystal",
        "pharma",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "corporate",
        "update",
        "cocrystal",
        "pharma",
        "inc",
        "see",
        "initiate",
        "phase",
        "study",
        "evaluating",
        "treatment",
        "influenza",
        "q4",
        "cocrystal",
        "pharma",
        "inc",
        "qtrly",
        "net",
        "loss",
        "million",
        "versus",
        "net",
        "loss",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}